Page 135 - SAMRC AnnualReport 2025-26
P. 135

P E R FOR M A NC E  I N FOR M A T I ON




            rationale, researchers investigated the potential   In partnership with the Gates Foundation and CP+
            repurposing of the anticancer kinase inhibitor     Associates, the Unit further established a mentorship
            berzosertib for the treatment of malaria. Using    programme to support mid-career scientists within
            preclinical studies in humanised mouse models      both the Unit and the Grand Challenges African Drug
            infected with Plasmodium falciparum, alongside     Discovery Accelerator (GC ADDA) network. Through
            advanced physiologically based pharmacokinetic     this initiative, participants received mentorship
            modelling, the Unit demonstrated that predicted    from experienced industry professionals in areas
            efficacious  doses  for  malaria  treatment  were   including  scientific  leadership,  communication,
            significantly  lower  than  the  clinically  established   career development, research responsibility, and
            maximum tolerated doses used in cancer therapy.    professional growth.
            This  work  provided  strong  evidence  supporting
            the feasibility of repurposing berzosertib as a novel   The Unit has additionally strengthened continental
            antimalarial candidate.                            collaboration by hosting visiting researchers from
                                                               institutions including the University of Limpopo, the
            Building Capacity Through                          University of Venda, the University of Zambia, the

            Training, Mentorship, and Support                  University of Ghana Noguchi Memorial Research
                                                               Institute,  and  the  Kwame  Nkrumah  University  of
            The Unit has also played a vital role in enhancing   Science and Technology (KNUST).
            scientific  capacity  across  Africa.  It  has  organised
            and hosted workshops on preclinical drug
            discovery and the use of artificial intelligence (AI)
            in drug discovery in South Africa, Zambia, Kenya,
            and Ghana. These workshops attracted hundreds
            of participants from across the continent and
            helped strengthen regional expertise in advanced
            biomedical research methodologies.






































                Dr. Mandy Mason, Dr. Zaahida Sheik-Ismail,         “AI2050 AI/ML Tools for Drug Discovery”
                Ferdinand Ndubi received their                     3-Day workshop co-hosted by H3D-
                “Best Poster Award”.                               Foundation with Ersilia in Nairobi, Kenya.





                                                           SA M R C  A N N U A L R EP O R T 2 0 2 5 / 2 0 2 6  133
   130   131   132   133   134   135   136   137   138   139   140